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a Saudi ArabiaBackground: Current published literature on hypertrophic cardiomyopathy (HCM) comes primarily from Western
populations. There is no published data on clinical and echocardiographic characteristics and long-term outcome of
HCM in an Arab population.
Methods: We conducted a retrospective analysis of all patients 16 years or older diagnosed with HCM at our insti-
tution. Detailed clinical and echocardiographic data were collected and outcome was analyzed.
Results: A total of 69 patients were identified as having HCM. The mean age was 42 ± 16 years with 71% male
patients. All patients were Saudi citizens with Arab ancestry. Details about family history and presenting symptoms
were available for 44 and 48 patients consecutively. Nine (18%) patients were asymptomatic and were diagnosed
based on abnormal cardiac auscultation. The commonest presenting symptoms were dyspnea with or without chest
pain and palpitations occurring in 40 (81%) patients. Only 4 (9%) of 44 patients had a family history of HCM and /or
sudden cardiac death (SCD). The most common ECG abnormality was left ventricular hypertrophy (LVH) present in
60 (86%) patients. The commonest septal hypertrophy morphology was mid-septal (catenoid) in 30 (43%) followed
by neutral in 23 (33%), basal septal (sigmoid) in 3 (4%) and apical in 6 (8%) patients. Twenty (28%) patients had evi-
dence of resting left ventricular cavity gradient of P30 mmHg. Eleven (16%) patients had evidence of biventricular
hypertrophy. Left ventricular ejection fraction was normal in 65 (94%) patients. Over a median (25–75 percentile) fol-
low-up of 7 years (4.5–10), only 3 patients died, all of non-cardiac causes. There were no cases of SCD during the
follow-up period. Six patients required an implantable cardioverter-defibrillator (ICD); five for primary prevention
and one for secondary prevention. Only 1 patient progressed to end stage dilated cardiomyopathy.
Conclusion: The natural history of hypertrophic cardiomyopathy in the Saudi population appears to be benign
with catenoid morphology being the most common septal hypertrophy pattern. Risk of SCD appears to be quite
low in this population.
 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.Keywords: Hypertrophic cardiomyopathy, Echocardiography, Septal morphology, Outcome
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Abbreviations
HCM hypertrophic cardiomyopathy
SCD sudden cardiac death
ICD implantable cardioverter-defibrillator
LVH left ventricular hypertrophy
LVOT left ventricular outflow tract
A4 apical four-chamber
PLAX parasternal long axis
DT deceleration time
Sa lateral and septal mitral annular systolic velocity
Ea lateral and septal mitral annular early diastolic
velocity
Aa lateral and septal mitral annular late diastolic
velocity
IVRT isovolumetric relaxation time
Ar-A difference (in milliseconds) between atrial systolic
flow reversal in pulmonary veins and mitral
A-wave duration
SAM systolic anterior motion of mitral leaflet
MR mitral regurgitation
ECG electrocardiogram
VT ventricular tachycardia
LVEF left ventricular ejection fraction
LVOTO left ventricular outflow tract obstruction
CMR cardiac magnetic resonance
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Hypertrophic cardiomyopathy (HCM) is anautosomal dominant familial disease due
to mutations of the myocardial sarcomeric con-
tractile proteins and occurs all over the world
across all races [1,2]. Hypertrophic cardiomyopa-
thy is defined by the presence of significant left
ventricular hypertrophy (LVH) in the absence of
secondary factors like systemic hypertension and
aortic stenosis [1]. The reported prevalence in
the West is about 0.2% or 1:500 in the general pop-
ulation [3]. Hypertrophic cardiomyopathy is a di-
verse disease with variable phenotypic
expression (i.e. LVH pattern) with a substantial
percentage of patients living a normal life without
any significant limitation and minimal risk of sud-
den cardiac death (SCD) [4–8]. However, some pa-
tients will have significant symptoms including
dyspnea, chest pain, syncope leading to substan-
tial morbidity as well as mortality reported to be
as high as 3–6% [6]. The most feared complication
of HCM is SCD due to ventricular arrhythmias
though it has been reported to occur in only 0.1–
1% of patients [5]. This apparent discrepancy be-
tween incidence of SCD in different studies has
been attributed to selection bias in tertiary care
centers [9]. The pattern of left ventricular hyper-
trophy is quite variable in HCM and is associated
with difference in morbidity and mortality. For in-
stance, it has been reported that apical HCM in
the Japanese population as well as those in North
America is associated with mostly benign outcome
[10,11]. The most common pattern of LVH is asym-
metric septal hypertrophy involving the basal
anterior septum as well as anterior free wall [12].
Despite initial reports of a close relationship be-
tween septal morphology and hemodynamics in
HCM, there has been no reported association be-
tween the patterns of hypertrophy and survival
[13]. Recently several groups have reported an
association of the septal morphology and sarco-
meric mutation by genotypes that may help in
better risk assessment and management of pa-
tients with HCM [14,15]. Resting left ventricular
outflow tract obstruction (LVOTO) has been
shown in some studies to be an independent pre-
dictor of subsequent heart failure and death [16].
Nearly all of the current published data on HCM
comes from Western populations. A PUBMED
search failed to show any published clinical or epi-
demiological study of HCM in the Arab/Middle
Eastern population. We sought to look at the clin-
ical and echocardiographic characteristics and
outcome of HCM in the Saudi population.Materials and methods
We retrospectively identified all patients be-
tween the ages of 16–80 years who were diagnosed
with hypertrophic cardiomyopathy from an echo-
cardiographic database between January 1997
and January 2007. HCM was diagnosed based on
echocardiographic evidence of LVHP 15 mm or
between 12 and 15 mm in presence of family his-
tory of HCM. Patients with secondary causes of
LVH like systemic hypertension and aortic steno-
sis or diagnosed infiltrative cardiomyopathy were
excluded. Detailed baseline clinical characteristics
including family history of HCM, presenting
symptoms, ECG abnormalities and echocardio-
graphic parameters were recorded. Patients were
followed up for a median (25–75 percentile) of 7
(4.5–10) years in out-patient clinic or via telephonic
contact in case of missed appointments. Primary
end point was cardiac mortality as a result of
SCD or progressive heart failure. Secondary out-
come was all cause mortality. The study was ap-
proved by the institutional review board.Echocardiographic data
Standard views were obtained using Philips iE-
33 (Phillips Healthcare, Andover, MA (USA) and
GE vivid E9 (GE Healthcare, USA). Two dimen-
sional (2-D), M-Mode, color Doppler echocardiog-
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can Society of Echocardiography recommenda-
tions [17]. All echocardiograms were reviewed by
two reviewers (NA, WA). Based on apical four-
chamber (A4) and parasternal long axis (PLAX)
views, we assessed the location and extent of the
septal hypertrophy at the basal, mid and apical
segments using 2-D image. If the 2-D image was
suboptimal, M-Mode image was used. Right ven-
tricular hypertrophy (RVH) was diagnosed as
right ventricular free wall thickness of >0.5 cm
measured in subcostal or PLAX 2-D or M-Mode
image. As suggested by Turer et al., the septal
morphology was classified into the following four
groups [15]:
 Sigmoid septum: maximal thickness in the basal anterior
septum (Fig. 1).
 Catenoid: maximal thickness in the mid septum (Fig. 2).
 Neutral: uniform thickness of the septum with ratio of max-
imal septal wall thickness in each septal segment of P0.8
(Fig. 3).
 Apical: maximum thickness in the apical septum (Fig. 4).
Detailed Doppler indices were recorded.
These included peak early (E) and late (A)Figure 2. Parasternal long axis (A) and apical 4-cham
Figure 1. Parasternal long axis (A) and apical 4-chtransmitral velocities, E/A ratio, deceleration
time (DT), lateral and septal mitral annular sys-
tolic (Sa), early diastolic (Ea) and with atrial con-
traction (Aa) velocities, isovolumetric relaxation
time (IVRT), difference (in milliseconds) be-
tween atrial systolic flow reversal in pulmonary
veins and mitral A-wave duration (Ar-A). For
calculating E/Ea ratio, we used the average (of
lateral and septal annulus) Ea velocity. Left
atrium (LA) volume was measured using the
area length method and indexed to body surface
area (BSA). The presence or absence of resting
LVOT obstruction based on modified Bernoulli
equation, systolic anterior motion of mitral leaf-
let (SAM) and presence of mitral regurgitation
(MR) were quantified. Electrocardiogram (ECG)
diagnosis of LVH was based on established
criteria [18].Data analysis
Continuous variables with normal distribution
were expressed as the mean ± SD and median
(25 and 75 percentile) when the distribution was
not normal. When comparing groups the inde-ber (B) view of catenoid (mid septal) morphology.
amber view (B) of sigmoid septal morphology.
Figure 4. Parasternal long axis (A) and apical 4-chamber view (B) of apical septal morphology.
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Figure 3. Parasternal long axis (A) and apical 4-chamber (B) view of neutral septal morphology.
Table 1. Clinical data.
Age (years) 42 ± 16
Male gender (%) 71
Atrial fibrillation (%) 15
Years follow-up after diagnosis 7 (4.5–10)
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pare continuous data or Mann–Whitney test when
appropriate and the Fisher’s exact test to compare
proportions. A P value <0.05 was considered sta-
tistically significant.Family history (n = 44)
No history (%) 86
Hypertrophic cardiomyopathy (%) 5
Sudden death (%) 9
Symptoms (n = 48)
Dyspnea (%) 65
Syncope (%) 4
Palpitation (%) 10
Miscellaneous (%) 2
No symptoms (%) 18
Values are mean ± SD for variables with a normal distribution and
median (25 and 75 percentile) for variables with a nonparametric
distribution.Results
A total of 69 patients were included in the study.
Table 1 shows the clinical characteristics of the
study population. Details about family history
and presenting symptoms were available for 44
and 48 patients respectively. Only 5 (11%) patients
had family history positive for HCM. Of a total of
48 patients, the most common presenting symp-
tom was dyspnea alone or with additional
symptoms like chest pain and palpitations, which
occurred in 40 (83%) patients. Eight (16%) patients
were asymptomatic. Only 2 patients presented
with syncope and 1 of them was found to have evi-
dence of non-sustained ventricular tachycardia
(VT) on 24-hour Holter monitor. After a mean fol-
low-up of 7 (4.5–10) years, there were no reports of
sudden cardiac death. A total of 6 (8.6%) patientsreceived an implantable cardioverter-defibrilator
(ICD), 5 for primary prevention (presence of risk
factors for sudden death) and 1 for secondary pre-
vention. Four of these 6 (i.e. 66.6%) had catenoid
morphology, 1 had sigmoid and 1 had neutral.
Only 1 patient progressed to end stage dilated
Table 2. Echocardiography data.
Left ventricular ejection fraction (%) 68 ± 13
Septal thickness (mm) 21 ± 6.9
Posterior wall thickness (mm) 13 ± 3.7
Left atrial volume index (ml/m2) 34 (27–54)
E/A ratio 1.5 (0.9–
2.1)
Deceleration time (ms) 219 ± 67
Isovolumic relaxation time (ms) 79 ± 29
Ar-AP 30 ms (%) 23
Sa (cm/s) 7.5 ± 2.9
Left ventricular outflow obstruction
(P30 mmHg, %)
28
Septal morphology
Neutral (%) 36
Catenoid (%) 42
Sigmoid (%) 12
Apical (%) 10
Biventricular hypertrophy (%) 16
Severe MR 7
Systolic anterior motion 39
Values are mean ± SD for variables with a normal distribution and
median (25 and 75 percentile) for variables with a nonparametric dis-
tribution. Sa: highest lateral or septal mitral annular systolic velocity;
Ar-A: difference (in milliseconds) between atrial systolic flow reversal in
pulmonary veins and mitral A-wave duration.
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device, however he died due to infectious compli-
cation prior to cardiac transplant. There were 2
additional non-cardiac deaths (due to renal failure
and non-Hodgkin’s lymphoma). Table 2 shows the
echocardiographic findings in the study popula-
tion. The most common septal morphology pat-
tern was catenoid and neutral that accounted for
78% of the patients. ECG criteria for LVH were
present in 60 (85.7%) patients. Paroxysmal atrial-
fibrillation was noted in 10 (15%) patients. Six
(8.5%) patients had normal ECG. Left ventricular
ejection fraction (LVEF) was normal or super nor-
mal (i.e. P70%) in 65 (94%) patients and was be-
tween 40% and 50% in 4 (5%) patients. Forty-two
patients (61%) had enlargement of the left atrium.
Prolonged reversal in the pulmonary vein (Ar-A)Table 3. Comparison between neutral and catenoid pattern of septa
Neutral (n
Age (years) 43 ± 18
Female gender (%) 28
Family history (%) 20
Dyspnea (%) 73
Left ventricular ejection fraction (%) 66 ± 16
Septal thickness (mm) 20 ± 8
Posterior wall thickness (mm) 13 ± 4
Left atrial volume index (ml/m2) 32 (21–53)
Left ventricular outflow obstruction (%) 24
LVOT Gradient (mmHg) 61 (47-64)
LVOT: Left ventricular outflow tract.was a common finding indicating increased LV
end-diastolic pressure. Systolic anterior motion
(SAM) of the mitral valve was found to be present
in 27 (39%) patients. Resting LVOT gradient
(P30 mmHg) was seen in 20 (28%) patients. Inter-
ventricular septum (IVS) was >30 mm in diameter
in 4 patients. Of these 4, 2 had no left ventricular
outflow tract obstruction (LVOTO) and 1 had
LVOTO of 64 mmHg and 1 with 22 mmHg. Only
1 of these 4 patients with severe LVH had SAM.
Thirty four (49%) patients had mild MR, 10 (14%)
had moderate, 5 (7%) had severe and 19 (27%)
had no MR. Table 3 shows a comparison between
clinical and echocardiographic characteristics of
patients with catenoid and neutral septal mor-
phology. There were no significant differences be-
tween the two patterns of septal hypertrophy
regarding age at presentation, gender, symptoms,
LVEF, septal thickness and presence of LVOTO.
The majority of our patients was either already
on beta-blockers at the time of diagnosis or was
placed on beta-blockers and/or calcium channel
blockers after diagnosis was established. Only 1
patient was on amiodarone. There were no pa-
tients on disopyramide.Discussion
We have presented the first study on the clinical
and echocardiographic characteristics and long-
term outcome of Arab HCM patients. The early
Western literature of higher morbidity and mor-
tality in HCM patients was primarily from special-
ized HCM centers and hence subject to selection
bias. Subsequent studies looking at the outcome
of HCM in more general population have shown
that the majority of patients with HCM have a be-
nign course. Although our hospital is a tertiary
care medical center, our study population showed
similar benign outcome. The majority of our pa-
tients had cardiac symptom including predomi-l hypertrophy.
= 25) Catenoid (n = 29) P value
41 ± 16 0.71
38 0.57
0 0.27
62 0.72
69 ± 10 0.36
22 ± 6 0.41
13 ± 4 0.48
34 (30–59) 0.20
38 0.38
30 (24–64) 0.35
FU
LL LEN
G
TH
 A
RTIC
LE
12 AHMED ET AL
HYPERTROPHIC CARDIOMYOPATHY IN SAUDI ARABIAN POPULATION:
CLINICAL AND ECHOCARDIOGRAPHIC CHARACTERISTICS AND OUTCOME ANALYSIS
J Saudi Heart Assoc
2014;26:7–13nantly dyspnea as well as chest pain and palpita-
tions; still there were no reports of SCD in this
study population, which is quite reassuring.
Despite being from a completely different ethnic
population, Arab patients also presented with cat-
enoid morphology as the commonest hypertrophy
pattern similar to western population [15]. This
may also have been influenced by the fact that
the average age in our study sample was 42 years,
and young age has been reported to be associated
more with catenoid morphology [14]. Turer et al.
[15], in their study, reported that ICD implantation
only occurred in patients with catenoid morphol-
ogy mostly for primary prevention. Our study also
showed that 66.6% of ICD’s were implanted in cat-
enoid morphology for primary prevention.
Though Turer et al. reported more advanced dia-
stolic dysfunction in patients with catenoid pat-
tern, we did not find any statistically significant
differences in clinical or echocardiographic find-
ings between the two predominant septal mor-
phological patterns i.e. catenoid and neutral
morphology. The septal morphological classifica-
tion as suggested by Turer et al. [15] and other
groups [14] may have clinical utility because of
the close association of catenoid morphology with
sarcomeric mutations, LGE on cardiac magnetic
resonance (CMR) imaging and that can help
selecting patients who should be referred for fur-
ther genetic testing since LGE on CMR has been
linked to increased ventricular arrhythmias in
HCM patients [14]. It is increasingly been recog-
nized that there is value in performing CMR in
all patients with HCM for better risk stratification
of patients who are at risk for ventricular arrhyth-
mias [19].
Resting ECG suggested the presence of LVH in
85.7% of patients. Since most patients in Saudi
Arabia are primarily seen by an internist at their
local Ministry of Health hospital, ECG can be a
valuable simple tool to detect HCM in asymptom-
atic or mildly symptomatic non-hypertensive pa-
tients who can then be referred to tertiary care
centers for further evaluation and management.
Although initially it was thought that all patients
with HCM have some degree of LVOT obstruc-
tion, latest literature suggests that only one third
of patients with HCM have resting LVOT obstruc-
tion (defined as gradient P30 mmHg) with an
additional one third having the non-obstructive
form of HCM [20]. Our data suggests similar find-
ings. Standard Doppler echocardiographic param-
eters for grading the severity of diastolic
dysfunction are considered to be not as valuable
in HCM patients as in other patients with cardiacdisorders [21–23]. Nearly all patients with HCM
have some degree of diastolic dysfunction. In the
present population, dyspnea and enlargement of
the left atrium was a common finding indicating
increased LV filling pressure.
Most of our patients required only beta-blockers
or calcium channel blockers with only 5 (7%)
requiring myomectomy for symptomatic relief.Limitations
Our study has several limitations. It is a retro-
spective study. It represents a single referral cen-
ter cohort and hence may not accurately reflect
HCM characteristics in the general Arab popula-
tion. However, the benign course in this referred
and hence somewhat biased population suggests
that HCM outcome in general population is per-
haps even better. Patients with systemic hyperten-
sion were excluded from the study because this
might explain the observed LV hypertrophy. Sys-
temic hypertension is a common diagnosis in the
population undergoing an echocardiographic
investigation and it is conceivable that some of
the patients excluded due to hypertension might
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